Crackdown on delaying tactics from pharmaceutical companies
Over the past few years, the European Commission has been investigating perceived anti-competitive practices in the pharmaceuticals sector. The commission launched an inquiry into the sector in January 2008, publishing its final report in July 2009. The final report found that the market was not functioning as it should be and that these deficiencies could largely be attributed to delays in entry of generic medicines to the market.
The commission concluded that originator drug companies were using a number of methods to extend the commercial life of their medicines and to prevent or delay the entry of generics. In particular, the commission has been monitoring patent settlement agreements, reflecting its concern that such agreements are being used as a means to delay the entry of generic products onto the market and to artificially extend the patent holder’s monopoly.
The first case worthy of mention involves Lundbeck and its drug citalopram, the antidepressant. The commission alleged that Lundbeck concluded agreements with generic competitors to prevent the market entry of competing generic versions following the expiry of its patents. Essentially, the commission claimed that Lundbeck paid substantial sums to the generic competitors in return for a delay in launching generic products onto the market. Following an investigation, the commission decided on 19 June 2013 that, in 2002, Lundbeck and the generic competitors were guilty of entering into such agreements and fines of €93.8m (£80m) and €52.2m were imposed upon Lunbeck and the other companies respectively…
If you are registered and logged in to the site, click on the link below to read the rest of the Walker Morris briefing. If not, please register or sign in with your details below.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Walker Morris
News from The Lawyer
Briefings from Walker Morris
Jackson, Denton, Mitchell… anyone involved with civil litigation over the last two years will have heard these names repeatedly and will be aware of their importance to compliance with the new rules.
While a headline glance at the Supreme Court’s judgment in this long-running case might give developers some encouragement a closer look reveals that the issues in play are not quite so straightforward.
Analysis from The Lawyer
Which firms are cutting it in this era of slimline rosters, and who are the GC new brooms making clean sweeps? The Lawyer can reveal all
The law school war shows no signs of ending. But we have, perhaps, reached the end of the beginning.